Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis.
ADCT©
Atopic dermatitis, tool, control, symptoms, impacts
reliability
responsiveness
validity
Journal
BMC dermatology
ISSN: 1471-5945
Titre abrégé: BMC Dermatol
Pays: England
ID NLM: 100968541
Informations de publication
Date de publication:
06 11 2019
06 11 2019
Historique:
received:
21
05
2019
accepted:
10
10
2019
entrez:
7
11
2019
pubmed:
7
11
2019
medline:
14
4
2020
Statut:
epublish
Résumé
The Atopic Dermatitis Control Tool (ADCT©) is a brief patient self-administered instrument designed and validated to assess atopic dermatitis (AD) control; six AD symptoms and impacts are evaluated over the past week, including overall severity of symptoms, days with intense episodes of itching, intensity of bother, problem with sleep, impact on daily activities, and impact on mood or emotions. This study assessed the reliability, validity, and responsiveness of the ADCT in a longitudinal context, and provided thresholds to identify meaningful within-person change. Data were from a prospective, longitudinal patient survey study of real-world effectiveness of dupilumab in patients with AD. Eligible patients completed a baseline survey before starting dupilumab and were followed at Months 1, 2, 3, and 6 post-initiation as they became eligible. Psychometric analyses confirmed internal consistency; Cronbach's α coefficients were consistently above the threshold of 0.70 across each follow-up; item-to-total correlations were above the threshold of r ≥ 0.50. High correlations between the ADCT and the Dermatology Life Quality Index (DLQI) and skin pain supported construct validity, while known-group validity was shown on Patient Global Assessment of Disease (PGAD) overall well-being subgroups with worse AD-related overall well-being having higher mean ADCT total scores at all time points. The ability of the ADCT to detect change was confirmed; the threshold for meaningful within-person change was estimated to be 5 points. Finally, test-retest reliability was confirmed in subgroups of patients with stable PGAD responses. Our findings confirm that the ADCT is a valid and reliable tool for assessing AD control.
Sections du résumé
BACKGROUND
The Atopic Dermatitis Control Tool (ADCT©) is a brief patient self-administered instrument designed and validated to assess atopic dermatitis (AD) control; six AD symptoms and impacts are evaluated over the past week, including overall severity of symptoms, days with intense episodes of itching, intensity of bother, problem with sleep, impact on daily activities, and impact on mood or emotions. This study assessed the reliability, validity, and responsiveness of the ADCT in a longitudinal context, and provided thresholds to identify meaningful within-person change.
METHODS
Data were from a prospective, longitudinal patient survey study of real-world effectiveness of dupilumab in patients with AD. Eligible patients completed a baseline survey before starting dupilumab and were followed at Months 1, 2, 3, and 6 post-initiation as they became eligible.
RESULTS
Psychometric analyses confirmed internal consistency; Cronbach's α coefficients were consistently above the threshold of 0.70 across each follow-up; item-to-total correlations were above the threshold of r ≥ 0.50. High correlations between the ADCT and the Dermatology Life Quality Index (DLQI) and skin pain supported construct validity, while known-group validity was shown on Patient Global Assessment of Disease (PGAD) overall well-being subgroups with worse AD-related overall well-being having higher mean ADCT total scores at all time points. The ability of the ADCT to detect change was confirmed; the threshold for meaningful within-person change was estimated to be 5 points. Finally, test-retest reliability was confirmed in subgroups of patients with stable PGAD responses.
CONCLUSIONS
Our findings confirm that the ADCT is a valid and reliable tool for assessing AD control.
Identifiants
pubmed: 31690295
doi: 10.1186/s12895-019-0095-3
pii: 10.1186/s12895-019-0095-3
pmc: PMC6833284
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
dupilumab
420K487FSG
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
15Subventions
Organisme : Sanofi
ID : NA
Pays : International
Organisme : Regeneron Pharmaceuticals Inc.
ID : NA
Pays : International
Références
Br J Dermatol. 2018 May;178(5):e332-e341
pubmed: 29672835
JAMA Dermatol. 2019 Feb 1;155(2):178-187
pubmed: 30540348
JAMA Dermatol. 2018 Aug 1;154(8):903-912
pubmed: 29971354
Arch Dermatol. 2004 Dec;140(12):1513-9
pubmed: 15611432
Dermatology. 2007;215 Suppl 1:18-26
pubmed: 18174690
Immunol Rev. 2011 Jul;242(1):233-46
pubmed: 21682749
J Dermatol. 2013 Sep;40(9):736-9
pubmed: 23834561
Ann Dermatol. 2010 May;22(2):125-37
pubmed: 20548901
Am J Clin Dermatol. 2017 Dec;18(6):825-835
pubmed: 28447213
J Eur Acad Dermatol Venereol. 2020 May;34(5):1026-1036
pubmed: 31587373
J Invest Dermatol. 2005 Oct;125(4):659-64
pubmed: 16185263
J Clin Epidemiol. 2007 Jan;60(1):34-42
pubmed: 17161752
J Am Acad Dermatol. 2014 Feb;70(2):338-51
pubmed: 24290431
J Allergy Clin Immunol. 2015 Jul;136(1):190-192.e3
pubmed: 25935107
Curr Med Res Opin. 2016 Oct;32(10):1645-1651
pubmed: 27240604
J Am Acad Dermatol. 2016 Mar;74(3):491-8
pubmed: 26777100
J Pediatr Psychol. 2009 Oct;34(9):917-28
pubmed: 19223279
Allergy. 2012 Sep;67(9):1111-7
pubmed: 22844983
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
Allergy. 2018 Jun;73(6):1284-1293
pubmed: 29319189
J Allergy Clin Immunol. 2014 Oct;134(4):800-7
pubmed: 25282560
Psychol Bull. 1979 Mar;86(2):420-8
pubmed: 18839484
Actas Dermosifiliogr. 2014 Jun;105(5):487-96
pubmed: 24630429
J Invest Dermatol. 2017 Jan;137(1):18-25
pubmed: 27771048
J Invest Dermatol. 2015 Apr;135(4):984-991
pubmed: 25521458
J Allergy Clin Immunol. 2018 Apr;141(4):1523-1526
pubmed: 29410314
J Allergy Clin Immunol. 2006 Jul;118(1):226-32
pubmed: 16815160
J Am Acad Dermatol. 2008 Mar;58(3):415-20
pubmed: 18280338
J Dermatolog Treat. 2010 Jan;21(1):34-44
pubmed: 20055695
J Allergy Clin Immunol. 2017 Apr;139(4S):S47-S48
pubmed: 28390476
Dermatology. 2015;230(1):27-33
pubmed: 25613671
Dermatology. 1993;186(1):23-31
pubmed: 8435513
Psychol Bull. 1992 Jul;112(1):155-9
pubmed: 19565683
J Allergy Clin Immunol. 2011 May;127(5):1110-8
pubmed: 21388665